See more : Euro Manganese Inc. (EUMNF) Income Statement Analysis – Financial Results
Complete financial analysis of NeuroSense Therapeutics Ltd. (NRSN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NeuroSense Therapeutics Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- GEK TERNA Holdings, Real Estate, Construction S.A. (GKTRF) Income Statement Analysis – Financial Results
- AEON Credit Service (Asia) Company Limited (0900.HK) Income Statement Analysis – Financial Results
- Platz Co., Ltd. (7813.T) Income Statement Analysis – Financial Results
- IntelliEPI Inc. (Cayman) (4971.TWO) Income Statement Analysis – Financial Results
- Imagin Medical Inc. (IMEXF) Income Statement Analysis – Financial Results
NeuroSense Therapeutics Ltd. (NRSN)
About NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 97.00K | 89.00K | 3.00K | 3.00K | 0.00 |
| Gross Profit | -97.00K | -89.00K | -3.00K | -3.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 7.27M | 6.42M | 3.08M | 2.50M | 898.00K |
| General & Administrative | 4.78M | 7.14M | 2.51M | 393.00K | 337.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.78M | 7.14M | 2.51M | 393.00K | 337.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 10.29M | 13.55M | 5.59M | 2.89M | 1.24M |
| Cost & Expenses | 10.29M | 13.55M | 5.59M | 2.89M | 1.24M |
| Interest Income | 178.00K | 91.00K | 0.00 | 61.00K | 18.00K |
| Interest Expense | 550.00K | 15.00K | 1.15M | 1.00K | 5.00K |
| Depreciation & Amortization | 97.00K | 89.00K | 3.00K | 3.00K | 1.24M |
| EBITDA | -10.63M | -13.38M | -2.88M | -2.83M | -1.25M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -12.05M | -13.55M | -5.59M | -2.89M | -1.24M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 769.00K | 1.21M | 1.55M | 60.00K | 13.00K |
| Income Before Tax | -11.28M | -12.34M | -4.04M | -2.83M | -1.22M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.14M | -1.55M | 1.00K | 5.00K |
| Net Income | -10.11M | -11.20M | -2.50M | -2.83M | -1.23M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.83 | -0.97 | -1.29 | -1.46 | -0.63 |
| EPS Diluted | -0.83 | -0.97 | -1.29 | -1.46 | -0.63 |
| Weighted Avg Shares Out | 13.64M | 11.50M | 1.94M | 1.94M | 1.94M |
| Weighted Avg Shares Out (Dil) | 13.64M | 11.50M | 1.94M | 1.94M | 1.94M |
NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients
PrimeC slowed disease progression by 43% (p=0.02) in pre-specified high-risk ALS patients Consistent data across subgroups underscore the potential of PrimeC to redefine the ALS treatment paradigm CAMBRIDGE, Mass. , May 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Announces First Quarter 2024 Business Update
CAMBRIDGE, Mass. , May 2, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
CAMBRIDGE, Mass. , April 22, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
Presentation by Massachusetts General Chair of Neurology Merit Cudkowicz, MD, shows both positive clinical effects and consistent trend toward impact on Neurofilament biomarker levels CAMBRIDGE, Mass. , April 18, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
Emerging Science (Late-Breaker Equivalent) Abstract To Be Presented At 5:30PM Local Time Highlights Phase 2 PARADIGM Outcomes CAMBRIDGE, Mass. , April 12, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
CAMBRIDGE, Mass. , April 10, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
NeuroSense will leverage its extensive experience in biomarker utilization to advance early diagnosis and treatment in the neurodegeneration field Lonza to develop, optimize, and qualify a method utilizing Neuron-Derived Exosomes ("NDEs"), set to be integrated into the clinical development program...
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update
CAMBRIDGE, Mass. , April 5, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
PrimeC demonstrated a clinically meaningful effect on quality of life and on complication free-survival for patients with ALS Standard ALS Measure ALSFRS-R already demonstrated a statistically significant effect of PrimeC on slowing down disease progression Further analysis of PARADIGM is on...
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
CAMBRIDGE, Mass. , Feb. 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Source: https://incomestatements.info
Category: Stock Reports